Skip to main navigation

About Us
Our Science
Our Portfolio
Investors & Media
Careers
- Join Us
- Current Openings
Contact

News Releases

Year

May 04, 2023

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Apr 27, 2023

Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting

Mar 30, 2023

Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

Mar 01, 2023

Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 23, 2023

Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock

Jan 17, 2023

Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Site - Nav - Investors & Media

Corporate Profile
News & Events
- News Releases
- Events & Presentations
Stock Information
Corporate Governance
Financials & Filings
- SEC Filings
Investor Resources

Presentation

Omega Therapeutics Corporate Overview cover 2022

Corporate Presentation – May 2023 6.8 MB

Investor & Media Contact

ir@omegatherapeutics.com

Site - Investor Tools

Print Page

Email Alerts

RSS Feeds

Contact IR

Search

Home
About Us
Our Science
Our Portfolio
Investors & Media
Careers
Contact Us

20 Acorn Park Drive
Cambridge, MA 02140

contact@omegatherapeutics.com

© Omega Therapeutics, Inc. 2023 All Rights Reserved.
All other trademarks referenced herein are properties of their respective owners.

Terms of use

Privacy Policy